June 2026
Serotonin
What June 2026's 18 new studies found, synthesized from the papers below. All Serotonin research →
The synthesis
Synthesized from 18 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Serotonin, 5-HT, serotonergic, 5-HT2A receptor, then ranked by relevance.
Research on serotonin in June 2026 focused heavily on the 5-HT2A receptor's role in psychedelic action and therapeutic effects. Studies consistently show that 5-HT2A signaling is central to psychedelic-induced neuroplasticity and behavioral effects, with some evidence that other receptors (5-HT2B, GPR143) modulate these outcomes. However, findings on endogenous DMT function and the direct physical interaction between 5-HT2A and mGluR2 are mixed or negative, indicating that the precise mechanisms remain debated. The evidence is largely preclinical or theoretical, with limited clinical data, so conclusions about human therapeutic efficacy are preliminary.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| No evidence for direct physical interaction of 5-HT 2A -mGluR2 receptors in vitro or in vivo 2026 | preclinical study | No effect | Found no evidence for mGluR2 and 5-HT2A receptor colocalization or oligomerization, supporting a model where mGluR2 modulates 5-HT2A via presynaptic inhibition of glutamate release rather than direct heterodimer interactions. | |
| Skin on Drugs: Psychotropic Compounds in Cutaneous Biology 2026 | review | Supports | Reviews evidence that psychotropic compounds, including serotonin receptor agonists, exert significant biological effects on skin through neurochemical and immunomodulatory pathways, suggesting novel dermatological therapeutic strategies. | |
| A Critical Evaluation of the Hypothesis that N,N-Dimethyltryptamine Maintains Neuroplasticity 2026 | theoretical or philosophical paper | Mixed | Argues that evidence for DMT's role in maintaining neuroplasticity is mixed and contested, with key findings not independently replicated and receptor affinity mismatches, and that clinical efficacy does not establish endogenous function. | |
| The Architecture of Ego Dissolution: A Mechanical-First Evaluation of N,N-Dimethyltryptamine at the Sigma-1 and 5-HT2A Interfaces 2026 | theoretical | Unclear | The abstract is empty, so the thesis is unclear; the title suggests a mechanical-first evaluation of DMT at sigma-1 and 5-HT2A interfaces. | |
| Synthesis and BiologicalEvaluation of 4‑Bromo-N,N-dimethyltryptamine(4-Br-DMT): A Synthetic BuildingBlock for Future Analog Development 2026 | experimental study | Mixed | Found that 4-Br-DMT has a serotonergic profile without psychedelic-like effects in mice but has a reduced safety profile compared to psilocin and DMT. | |
| Blocking 5-HT2B receptors abolishes psilocybin’s efficacy in the rat forced swim test 2026 | experimental study | Supports | Found that blocking 5-HT2B receptors abolishes psilocybin's rapid and sustained antidepressant-like effects in the forced swim test but does not affect the head-twitch response, indicating 5-HT2B is required for antidepressant efficacy. | |
| A Critical Evaluation of the Hypothesis that N,N-Dimethyltryptamine has Endogenous Functions 2026 | theoretical or philosophical paper | Mixed | Argues that evidence for an endogenous physiological function of DMT is mixed and contested, with key findings not independently replicated and receptor affinity mismatches, and that clinical efficacy does not establish endogenous function. | |
| Decoding the serotonin–alcohol crosstalk: the role of central serotonergic dysregulation in alcohol use disorder 2026 | review | Supports | Reviews evidence that reduced serotonin activity increases vulnerability to alcohol use disorder, particularly Cloninger's type II, and that serotonergic psychedelic-assisted therapies may offer treatment potential by activating prefrontal 5-HT2A receptors. | |
| The Effects of Serotonergic systems on Cognitive Flexibility and Perseverative Thinking: a comparison between SSRI, classical psychedelics, and acute tryptophan depletion in a Multilevel Meta-Analysis 2026 | multilevel meta-analysis | 2030 | Mixed | Found that serotonergic interventions robustly reduce perseverative thinking but do not consistently alter performance on laboratory measures of cognitive flexibility. |
| Psychedelics and related compounds in cluster headache and migraine: a systematic review and meta-analysis v1 2026 | systematic review and meta-analysis protocol | Unclear | Describes a planned systematic review and meta-analysis to evaluate the efficacy and safety of serotonergic psychedelics and related compounds for cluster headache and migraine; no results are reported. | |
| Serotonergic psychedelics for Autism spectrum disorder: Neurobiological mechanisms and translational prospects. 2026 | review | Supports | Reviews evidence that serotonergic psychedelics may counteract core ASD pathophysiology by enhancing neuroplasticity, reducing neuroinflammation, and inducing less constrained brain states, warranting further clinical trials. | |
| Sex-Specific Effects of Psilocybin Versus Escitalopram on Anxiety and Anhedonia: A Bayesian Reanalysis of Antidepressant Treatment Outcomes 2026 | randomized controlled trial | Mixed | Found sex-specific effects: women receiving psilocybin showed greater reductions in anxiety than men, while women receiving escitalopram showed greater reductions in anhedonia than men. | |
| Serotonin 2A receptor binding, functional activity, and in vitro metabolism of two trideuteromethoxy 2C-B isotopologues. 2026 | in vitro study | Supports | Found that deuteration of the ring methoxy groups of 2C-B increased affinity at 5-HT2A receptors but did not affect functional activity in calcium release or β-arrestin 2 recruitment assays. | |
| IARS Emery Brown Award 2026: Anesthetics and Serotonergic Psychedelics May Promote Therapeutic Neuroplasticity by Destabilizing Pathological Neuronal Circuitry. 2026 | theoretical or philosophical paper | Supports | Argues that anesthetics and serotonergic psychedelics may promote therapeutic neuroplasticity by destabilizing pathological neuronal circuitry. | |
| Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in rats. 2026 | experimental animal study | Supports | Found that a single psilocybin dose improved sensorimotor function, restored serotonin 2A receptor binding, and reduced microglial cell counts in rats one year after fluid-percussion traumatic brain injury. | |
| Novel 5,6-Bicyclic Compounds as 5-HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches 2026 | theoretical | Unclear | The abstract describes novel 5,6-bicyclic compounds as 5-HT2A receptor agonists for treating depression, anxiety, substance abuse, and headaches, but no empirical data are reported. | |
| Enhanced effect of the hallucinogen DOI in L-DOPA receptor Gpr143-deficient mice. 2026 | experimental study | Supports | Found that GPR143 negatively regulates 5-HT2A receptor signaling and attenuates behavioral responses to hallucinogens, as DOI-induced effects were enhanced in GPR143 knockout mice. | |
| Explainable Artificial Intelligence (xAI) for 5-HT2A Receptor Binding Affinity of New Psychoactive Substances. 2026 | classification model development and validation | Supports | Developed machine learning models that achieved precisions and recalls up to 93% and 92% for predicting 5-HT2A binding affinity of new psychoactive substances, supporting their suitability for such predictions. |
Found no evidence for mGluR2 and 5-HT2A receptor colocalization or oligomerization, supporting a model where mGluR2 modulates 5-HT2A via presynaptic inhibition of glutamate release rather than direct heterodimer interactions.
preclinical study
Reviews evidence that psychotropic compounds, including serotonin receptor agonists, exert significant biological effects on skin through neurochemical and immunomodulatory pathways, suggesting novel dermatological therapeutic strategies.
review
Argues that evidence for DMT's role in maintaining neuroplasticity is mixed and contested, with key findings not independently replicated and receptor affinity mismatches, and that clinical efficacy does not establish endogenous function.
theoretical or philosophical paper
The abstract is empty, so the thesis is unclear; the title suggests a mechanical-first evaluation of DMT at sigma-1 and 5-HT2A interfaces.
theoretical
Found that 4-Br-DMT has a serotonergic profile without psychedelic-like effects in mice but has a reduced safety profile compared to psilocin and DMT.
experimental study
Found that blocking 5-HT2B receptors abolishes psilocybin's rapid and sustained antidepressant-like effects in the forced swim test but does not affect the head-twitch response, indicating 5-HT2B is required for antidepressant efficacy.
experimental study
Argues that evidence for an endogenous physiological function of DMT is mixed and contested, with key findings not independently replicated and receptor affinity mismatches, and that clinical efficacy does not establish endogenous function.
theoretical or philosophical paper
Reviews evidence that reduced serotonin activity increases vulnerability to alcohol use disorder, particularly Cloninger's type II, and that serotonergic psychedelic-assisted therapies may offer treatment potential by activating prefrontal 5-HT2A receptors.
review
Found that serotonergic interventions robustly reduce perseverative thinking but do not consistently alter performance on laboratory measures of cognitive flexibility.
multilevel meta-analysis Sample size: 2030
Describes a planned systematic review and meta-analysis to evaluate the efficacy and safety of serotonergic psychedelics and related compounds for cluster headache and migraine; no results are reported.
systematic review and meta-analysis protocol
Reviews evidence that serotonergic psychedelics may counteract core ASD pathophysiology by enhancing neuroplasticity, reducing neuroinflammation, and inducing less constrained brain states, warranting further clinical trials.
review
Found sex-specific effects: women receiving psilocybin showed greater reductions in anxiety than men, while women receiving escitalopram showed greater reductions in anhedonia than men.
randomized controlled trial
Found that deuteration of the ring methoxy groups of 2C-B increased affinity at 5-HT2A receptors but did not affect functional activity in calcium release or β-arrestin 2 recruitment assays.
in vitro study
Argues that anesthetics and serotonergic psychedelics may promote therapeutic neuroplasticity by destabilizing pathological neuronal circuitry.
theoretical or philosophical paper
Found that a single psilocybin dose improved sensorimotor function, restored serotonin 2A receptor binding, and reduced microglial cell counts in rats one year after fluid-percussion traumatic brain injury.
experimental animal study
The abstract describes novel 5,6-bicyclic compounds as 5-HT2A receptor agonists for treating depression, anxiety, substance abuse, and headaches, but no empirical data are reported.
theoretical
Found that GPR143 negatively regulates 5-HT2A receptor signaling and attenuates behavioral responses to hallucinogens, as DOI-induced effects were enhanced in GPR143 knockout mice.
experimental study
Developed machine learning models that achieved precisions and recalls up to 93% and 92% for predicting 5-HT2A binding affinity of new psychoactive substances, supporting their suitability for such predictions.
classification model development and validation
Points of agreement
- 5-HT2A receptor signaling is central to psychedelic action and therapeutic effects.
- Psychedelics like psilocybin may enhance neuroplasticity and reduce neuroinflammation.
- Serotonergic interventions can reduce perseverative thinking.
- Evidence for endogenous DMT function is mixed and contested.
Conflicts
- One study found no evidence for mGluR2-5-HT2A heterodimers, while another suggests GPR143 modulates 5-HT2A signaling, indicating different regulatory mechanisms.
- DMT concentrations are reported as nM by some but below detection limit by others, leading to conflicting interpretations of endogenous function.
- Psilocybin's antidepressant effects are attributed to 5-HT2B in one study, while other studies emphasize 5-HT2A, suggesting receptor subtype specificity is debated.
Gaps
- Durability of therapeutic effects beyond short-term follow-up is not established.
- Most studies are preclinical or theoretical; clinical trials are limited.
- Sex-specific effects are understudied, with only one RCT reporting sex differences.
- The role of specific 5-HT receptor subtypes (e.g., 5-HT2B vs 5-HT2A) in therapeutic outcomes is not fully resolved.
- Endogenous DMT function remains unconfirmed due to replication and measurement issues.
- Long-term safety and tolerability of psychedelics in clinical populations are not well characterized.